Intracellular Therapies Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 561

Employees

  • Stock Symbol
  • ITCI

Stock Symbol

  • Share Price
  • $127.01
  • (As of Friday Closing)

Intracellular Therapies General Information

Description

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Contact Information

Formerly Known As
Oneida Resources Corp.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 135 Route 202/206
  • Suite 6
  • Bedminster, NJ 07921
  • United States
+1 (646)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 135 Route 202/206
  • Suite 6
  • Bedminster, NJ 07921
  • United States
+1 (646)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intracellular Therapies Stock Performance

As of 07-Feb-2025, Intracellular Therapies’s stock price is $127.01. Its current market cap is $13.5B with 106M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$127.01 $127.12 $62.78 - $128.00 $13.5B 106M 2.33M -$0.87

Intracellular Therapies Financials Summary

As of 30-Sep-2024, Intracellular Therapies has a trailing 12-month revenue of $613M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 6,727,030 6,417,029 4,409,462 3,812,909
Revenue 612,784 462,175 249,132 81,708
EBITDA (121,086) (158,853) (262,970) (285,155)
Net Income (86,370) (139,674) (256,256) (284,126)
Total Assets 1,324,445 728,295 754,780 489,922
Total Debt 17,709 16,938 20,041 25,407
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Intracellular Therapies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Intracellular Therapies‘s full profile, request access.

Request a free trial

Intracellular Therapies Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Intracellular Therapies‘s full profile, request access.

Request a free trial

Intracellular Therapies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the centr
Drug Discovery
Bedminster, NJ
561 As of 2022

Washington, DC
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intracellular Therapies Competitors (56)

One of Intracellular Therapies’s 56 competitors is Vanda Pharmaceuticals, a Formerly VC-backed company based in Washington, DC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vanda Pharmaceuticals Formerly VC-backed Washington, DC
Rigel Pharmaceuticals Formerly VC-backed South San Francisco, CA
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN
Cerecin Venture Capital-Backed Denver, CO
GT Biopharma Corporation Brisbane, CA
You’re viewing 5 of 56 competitors. Get the full list »

Intracellular Therapies Patents

Intracellular Therapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023320312-A1 Novel salts and crystals Pending 30-Jul-2022
US-20230372336-A1 Novel methods Pending 18-May-2022
US-20240122924-A1 Novel methods Pending 18-May-2022
AU-2023272111-A1 Novel methods Pending 18-May-2022
AU-2023236707-A1 Organic compounds Pending 14-Mar-2022 C07D471/16
To view Intracellular Therapies’s complete patent history, request access »

Intracellular Therapies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intracellular Therapies ESG

Risk Overview

Risk Rating

Updated October, 15, 2024

33.93 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Pharmaceuticals

Subindustry

of 425

Rank

Percentile

To view Intracellular Therapies’s complete esg history, request access »

Intracellular Therapies FAQs

  • When was Intracellular Therapies founded?

    Intracellular Therapies was founded in 2002.

  • Where is Intracellular Therapies headquartered?

    Intracellular Therapies is headquartered in Bedminster, NJ.

  • What is the size of Intracellular Therapies?

    Intracellular Therapies has 561 total employees.

  • What industry is Intracellular Therapies in?

    Intracellular Therapies’s primary industry is Drug Discovery.

  • Is Intracellular Therapies a private or public company?

    Intracellular Therapies is a Public company.

  • What is Intracellular Therapies’s stock symbol?

    The ticker symbol for Intracellular Therapies is ITCI.

  • What is the current stock price of Intracellular Therapies?

    As of 07-Feb-2025 the stock price of Intracellular Therapies is $127.01.

  • What is the current market cap of Intracellular Therapies?

    The current market capitalization of Intracellular Therapies is $13.5B.

  • What is Intracellular Therapies’s current revenue?

    The trailing twelve month revenue for Intracellular Therapies is $613M.

  • Who are Intracellular Therapies’s competitors?

    Vanda Pharmaceuticals, Rigel Pharmaceuticals, Apexian Pharmaceuticals, Cerecin, and GT Biopharma are some of the 56 competitors of Intracellular Therapies.

  • What is Intracellular Therapies’s annual earnings per share (EPS)?

    Intracellular Therapies’s EPS for 12 months was -$0.87.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »